Effective bladder preservation strategy with low-dose radiation therapy and concurrent intrarrterial chemotherapy for muscle-invasive bladder cancer
| Autor: | Shunsuke Furutani, Hiro-omi Kanayama, Takashi Kawanaka, Kyoh Yamashita, Akiko Kubo, Yoshihiro Takegawa, Seiji Iwamoto, Hitoshi Ikushima, Takaharu Kudoh, Kyohsuke Osaki, Hiromu Nishitani |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Urology Multimodality Therapy Cystectomy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intra-Arterial Combined Modality Therapy Neoplasm Invasiveness Radiology Nuclear Medicine and imaging Survival rate Retrospective Studies Radiation Bladder cancer business.industry Radiotherapy Dosage medicine.disease Survival Rate Radiation therapy Treatment Outcome Urinary Bladder Neoplasms Low Dose Radiation Therapy Female Neoplasm Recurrence Local business Chemoradiotherapy |
| Zdroj: | Radiation Medicine. 26:156-163 |
| ISSN: | 1862-5274 0288-2043 |
| DOI: | 10.1007/s11604-007-0211-x |
| Popis: | The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT).. Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment.Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity.Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink